LEONARDI, LUCA
 Distribuzione geografica
Continente #
NA - Nord America 2.167
EU - Europa 1.316
AS - Asia 1.133
SA - Sud America 172
AF - Africa 57
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.889
Nazione #
US - Stati Uniti d'America 2.122
IT - Italia 717
SG - Singapore 477
HK - Hong Kong 213
BR - Brasile 144
CN - Cina 119
IN - India 119
GB - Regno Unito 85
DE - Germania 74
SE - Svezia 72
RU - Federazione Russa 55
FI - Finlandia 54
JP - Giappone 54
AU - Australia 42
NL - Olanda 36
KR - Corea 35
FR - Francia 30
CA - Canada 26
AT - Austria 25
ID - Indonesia 24
IE - Irlanda 24
BE - Belgio 19
BG - Bulgaria 17
TG - Togo 17
ZA - Sudafrica 17
TR - Turchia 15
VN - Vietnam 14
AR - Argentina 13
ES - Italia 10
RO - Romania 10
UA - Ucraina 10
CZ - Repubblica Ceca 9
HU - Ungheria 9
AL - Albania 8
IQ - Iraq 8
MA - Marocco 8
MX - Messico 8
PK - Pakistan 8
SA - Arabia Saudita 8
BD - Bangladesh 7
CH - Svizzera 7
EC - Ecuador 7
IR - Iran 7
PL - Polonia 7
EE - Estonia 6
RS - Serbia 6
LI - Liechtenstein 5
BA - Bosnia-Erzegovina 4
CO - Colombia 4
IL - Israele 4
JM - Giamaica 4
GL - Groenlandia 3
GR - Grecia 3
LT - Lituania 3
SC - Seychelles 3
TN - Tunisia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
DZ - Algeria 2
HR - Croazia 2
IS - Islanda 2
KE - Kenya 2
KG - Kirghizistan 2
LB - Libano 2
NO - Norvegia 2
PS - Palestinian Territory 2
AO - Angola 1
BT - Bhutan 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
JO - Giordania 1
MD - Moldavia 1
MN - Mongolia 1
MZ - Mozambico 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.889
Città #
Singapore 312
Fairfield 286
Rome 229
Hong Kong 208
Ashburn 183
Chandler 178
Woodbridge 122
Houston 120
Seattle 117
Cambridge 103
Milan 89
Santa Clara 81
Wilmington 70
San Paolo di Civitate 59
Dearborn 57
Princeton 47
Beijing 42
Lawrence 39
New York 39
Los Angeles 37
Cosenza 32
Boston 27
Munich 27
San Diego 25
Ann Arbor 24
Jakarta 23
Dublin 21
Jungnang-gu 21
Plano 21
Tokyo 20
Millbury 19
Lomé 17
Sofia 17
Sydney 17
Vienna 17
Helsinki 16
Melbourne 16
Moscow 15
Bengaluru 14
Turku 14
Andover 13
Boardman 13
Norwalk 13
Fuzhou 12
London 12
Nagoya 12
Naples 12
São Paulo 12
Waanrode 12
Nuremberg 11
Toronto 11
Chicago 9
Falkenstein 8
Florence 8
Lappeenranta 8
Nanjing 8
Colorado Springs 7
Council Bluffs 7
Fasano 7
Hefei 7
Manchester 7
Paris 7
Plymouth 7
Ponzano Veneto 7
Seoul 7
Belo Horizonte 6
Brisbane 6
Dallas 6
Frankfurt am Main 6
Hanoi 6
Bremen 5
Brussels 5
Budapest 5
Edinburgh 5
Fremont 5
Palermo 5
Rio de Janeiro 5
San Francisco 5
San Mateo 5
Tirana 5
Brasília 4
Buffalo 4
Carol Stream 4
Federal 4
Izmir 4
Kyoto 4
Madrid 4
Mannheim 4
Mexico City 4
Montreal 4
Newark 4
Ottawa 4
Pisa 4
Quito 4
Stockholm 4
Tallinn 4
Turin 4
Yubileyny 4
Zurich 4
Alghero 3
Totale 3.217
Nome #
Use of dynamic movement orthoses to improve gait stability and trunk control in ataxic patients 324
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT). a multicentre, randomised, placebo-controlled, phase 3 trial 182
Early-onset optic neuropathy as initial clinical presentation in SPG7 131
Riluzole in patients with hereditary cerebellar ataxia. a randomised, double-blind, placebo-controlled trial 131
Gait patterns in patients with hereditary spastic paraparesis 110
A wearable proprioceptive stabilizer for rehabilitation of limb and gait ataxia in hereditary cerebellar ataxias. A pilot open-labeled study 108
Cerebellum and neuropsychiatric disorders: Insights from ARSACS 106
'When atlastin meets spastin' 106
Nerve high-resolution ultrasonography in peripheral nerve injuries associated with supracondylar humeral fractures in children 105
Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up 104
GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNγ administration in FRDA patients 103
Pigmentary degenerative maculopathy as prominent phenotype in an Italian SPG56/CYP2U1 family 102
Attrv in lazio-italy: A high-prevalence region in a non-endemic country 101
Quantitative sensory testing and skin biopsy findings in late‐onset ATTRv pre‐symptomatic carriers: relationships with predicted time of disease onset (PADO) 99
Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis 99
Acute optic neuropathy associated with a novel MFN2 mutation 99
Spinocerebellar ataxia type 3 in Italy. time to change mind 98
Spinocerebellar ataxia type 10 in Peru: the missing link in the Amerindian origin of the disease 97
Nerve high resolution ultrasonography in Tangier disease 97
Longitudinal neurophysiological assessment of intramuscular type-A botulin toxin in healthy humans 96
Local stability of the trunk in patients with degenerative cerebellar ataxia during walking 93
Widening the phenotypical spectrum of EGR2-related CMT: unusual phenotype for R409W mutation 93
Progression of gait ataxia in patients with degenerative cerebellar disorders. A 4-year follow-up study 91
Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database 90
Electrophysiological abnormalities in iatrogenic botulism: Two case reports and review of the literature 85
Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients 82
Muscle MRI in immune-mediated necrotizing myopathy (IMNM). implications for clinical management and treatment strategies 81
Novel ACTA1 mutation causes late-presenting nemaline myopathy with unusual dark cores 74
Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials 74
Skin biopsy and quantitative sensory assessment in an Italian cohort of ATTRv patients with polyneuropathy and asymptomatic carriers: possible evidence of early non-length dependent denervation 73
Sensory ataxia as a prominent clinical presentation in three families with mutations in CYP7B1 72
Gender effect on cardiac involvement in myotonic dystrophy type 1 72
Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study 71
Comparison of quantitative muscle ultrasound and whole-body muscle MRI in facioscapulohumeral muscular dystrophy type 1 patients 71
Chronic inflammatory demyelinating polyradiculoneuropathy: can we make a diagnosis in patients not fulfilling electrodiagnostic criteria? 71
Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and diagnostic test findings 69
Distal upper limb involvement in myasthenia-myositis association 67
ATTRv amyloidosis Italian Registry: clinical and epidemiological data 64
Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy 61
Impact of environmental factors and physical activity on disability and quality of life in CIDP 61
High-resolution ultrasound of peripheral nerves in late-onset hereditary transthyretin amyloidosis with polyneuropathy: similarities and differences with CIDP 61
Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) 60
Risk of disease relapse, safety and tolerability of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies 57
The neurophysiological lesson from the Italian CIDP database 54
null 53
Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy 53
Nerve ultrasonography findings as possible pitfall in differential diagnosis between hereditary transthyretin amyloidosis with polyneuropathy and chronic inflammatory demyelinating polyneuropathy 52
Neuropathic pain experience in symptomatic and presymptomatic subjects carrying a transthyretin gene mutation 51
Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors 50
Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy 50
Prominent mitochondrial pathology in a case of refractory dermatomyositis: coincidence or concause? 50
Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP 49
Relevance of diagnostic investigations in chronic inflammatory demyelinating poliradiculoneuropathy. Data from the Italian CIDP database 48
Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: data from an early- access program in Italy 46
Muscle hypertrophy following acquired neurogenic injury: systematic review and analysis of existing literature 44
Nerve high-resolution ultrasound in a 2-years follow-up of radial nerve palsy related to humeral shaft fractures 42
Assessment of diagnostic criteria for multifocal motor neuropathy in patients included in the Italian database 41
Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis 39
Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran 39
Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants 38
Elevated serum concentrations of GFAP in hereditary transthyretin amyloidosis since pre-symptomatic stages 34
De novo mutations in SPG3A: a challenge in differential diagnosis and genetic counselling 34
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study 32
Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis? 28
Exploring Cardiac Sympathetic Denervation in Transthyretin-Mediated Hereditary Amyloidosis (ATTRv): Insights from 123I-mIBG Scintigraphy 23
Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers 21
Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy 20
Patisiran in ATTRv amyloidosis with polyneuropathy: "PatisiranItaly" multicenter observational study 17
Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience 14
Comparative Analysis of SiMoA and Ella Immunoassay Platforms for Measuring Serum Neurofilament Light Chain Levels in ATTRv With Polyneuropathy and Presymptomatic Carriers 12
Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how 8
Peripherin, A New Promising Biomarker in Neurological Disorders 6
Minimal invasive biopsies are highly sensitive for amyloid detection in hereditary transthyretin amyloidosis with polyneuropathy 5
null 4
Nerve ultrasound in the diagnosis of inflammatory neuropathies 1
Totale 5.149
Categoria #
all - tutte 17.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.653


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202023 0 0 0 0 0 0 0 0 0 0 0 23
2020/2021280 17 22 10 29 16 10 19 15 32 55 29 26
2021/2022632 64 25 45 30 73 26 24 48 39 29 143 86
2022/2023758 96 136 18 86 90 85 30 47 72 25 49 24
2023/2024685 21 57 25 44 42 85 61 72 19 100 89 70
2024/20251.877 49 172 92 86 114 119 80 110 260 182 179 434
Totale 5.149